Keywords: Catalyst Pharma, Cocaine addiction, Vigabatrin, CPP-109, Trial delay
Catalyst Pharma shares fall after mid-stage cocaine addiction trial delayed
Article | 27 September 2012
Catalyst Pharmaceutical Partners (Nasdaq: CPRX) shares fell 18.5% to $1.50 in premarket trading yesterday after it said that mid-stage results of its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
